MA(Medical Affairs)는 2030년까지 제약 업계의 초석이 되기 위해 혁신적인 진화를 이루고자 합니다.
MA(Medical Affairs)는 R&D 및 커머셜 팀과 함께 지원 기능에서 전략적 리더십 역할로 전환하고, AI 및 원격의료와 같은 디지털 기술을 통합하여 진화할 것입니다. 또한, MA(Medical Affairs)는 환자 중심의 전략을 중시하고 환자의 목소리를 대변하여 치료가 환자의 요구를 충족시킬 수 있도록 할 것입니다.
이번 보고서에서는 MA(Medical Affairs) 컨설턴트이자 MSL(Medical Science Liaison)의 CEO인 Samuel Dyer를 만나 이야기를 들어보았습니다. Medical Science Liaison(MSL) 협회로부터 MA(Medical Affairs)의 진화에 있어 환자 중심적 접근과 RWE의 역할에 대해 들어보고 그 내용을 정리해 보았습니다.
Medical affairs is poised for a transformative evolution by 2030, becoming a cornerstone of the pharmaceutical industry.
Transitioning from a support function to a strategic leadership role alongside R&D and commercial teams, medical affairs' evolution is driven by the integration of digital technologies like AI and telehealth. Furthermore, medical affairs will focus on patient-centric strategies, representing patient voices to ensure treatments meet their needs.
FirstWord spoke to Samuel Dyer, medical affairs consultant and CEO of the Medical Science Liaison (MSL) Society, about the role of patient-centric approaches and RWE in the evolution of medical affairs.
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.